Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.


Brentuximab vedotin (BV) is an antibody-drug-conjugate directed against CD30 antigen, recently approved for the treatment of relapsed anaplastic large-cell lymphomas (ALCL). It has further been suggested that a significant proportion of peripheral T-cell lymphomas (PTCL) may be potential candidates for CD30-targeting strategies. Indeed, besides ALCL, CD30… (More)
DOI: 10.3324/haematol.2015.135400


3 Figures and Tables


Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.